ESR1 and breast carcinoma: The more aggressive behavior observed in HR+ metastatic breast cancer is hypothesized to occur through multiple mechanisms including: (i) loss of the estrogen receptor (ER), (ii) acquisition of additional mutations, and/or (iii) alterations in estrogen and growth factor-mediated signaling cascades [3,4].